Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms

Caramazza, Domenica; Caracciolo, Clementina; Barone, Rita; Malato, Alessandra; Saccullo, Giorgia; Cigna, Valentina; Berretta, Salvatore; Schinocca, Luciana; Quintini, Gerlando; Abbadessa, Vincenzo; Raimondo, Francesco Di; Siragusa, Sergio

doi:10.1007/s00277-009-0706-x

Cited by 29 publications

(22 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10,12,15,16 This study confirms previous observations on the association between leukocytosis and worse survival in ET. 10,12,16 The role of leukocytosis on thrombosis prediction in ET has been largely discussed in the last years as many investigators found a correlation with thrombosis, 3,[17][18][19][20] others did not, 21,22 and others found a relationship between increase of leukocyte count over time and thrombosis. 23 Although all of these factors should ideally be assessed in a prospective study, the IPSET model undoubtedly states that leukocytosis Ͼ 11 ϫ 10 9 /L is a predictor of survival as well as history of thrombosis.…”

Section: Discussionmentioning

confidence: 99%

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

Passamonti

Thiele

Girodon

et al. 2012

Blood

Self Cite

227

185

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

Passamonti

Thiele

Girodon

et al. 2012

Blood

Self Cite

227

185

View full text Add to dashboard Cite

show abstract

“…JAK2 V617F is associated with a higher incidence of thrombotic events [28,29,34,35]. In addition, patients bearing the JAK2 V617F mutation have higher hemoglobin levels, and higher WBC and lower platelet counts [34].…”

Section: Discussionmentioning

confidence: 99%

“…The WBC count was found to be an independent risk factor for thrombosis in MPN patients [29,30,31,32]. …”

Section: Discussionmentioning

confidence: 99%

Clinical and Laboratory Significance of Defective P2Y<sub>12</sub> Pathway Function in Patients with Myeloproliferative Neoplasms: A Pilot Study

Chang

Shih²,

Michelson³

et al. 2013

Acta Haematol

View full text Add to dashboard Cite

Background: Patients with myeloproliferative neoplasms (MPN) have an increased risk for thrombosis and bleeding and show a defect in adenosine diphosphate (ADP)-induced platelet aggregation. This risk of thrombosis is further increased in MPN patients bearing the JAK2V617F mutation. Two ADP receptors, P2Y₁ and P2Y₁₂, are present on platelets. Although the pattern of defective ADP-induced platelet aggregation in MPN suggests an abnormality in the P2Y₁₂ pathway, no previous studies have specifically evaluated P2Y₁₂ function in MPN or the relationship between P2Y₁₂ function and the JAK2V617F mutation. Methods: Forty-one MPN patients were enrolled, including 24 with essential thrombocythemia (ET), 16 with polycythemia vera (PV) and 1 with primary myelofibrosis. Platelet P2Y₁₂ function in MPN was evaluated by flow-cytometric measurement of the phosphorylation of vasodilator-stimulated phosphoprotein (VASP). Clinical data were collected by review of medical records. JAK2V617F mutation was detected by allele-specific polymerase chain reaction. JAK2V617F allele burden was measured by the pyrosequencing method. Results: In patients with MPN, platelet P2Y₁₂ function determined by VASP platelet reactivity index (PRI) was inversely correlated with platelet and white blood cell (WBC) counts. In subgroup analysis, PRI was inversely correlated with platelet and WBC counts in PV. PRI was also inversely correlated with platelet counts in ET, but the correlation of PRI and WBC counts did not reach statistical significance. Eight of the 41 patients had a history of thrombosis and only 2 had a bleeding history. Neither thrombosis nor bleeding patients were found to have significantly different PRIs. JAK2V617F mutation data were available in 35 cases. PRI was not different between JAK2V617F mutation and wild-type patients but PRI had a trend towards an inverse correlation with JAK2V617F allele burden for patients with mutations. Conclusions: The present study provides the first explicit demonstration of a defect in the P2Y₁₂ pathway in platelets of patients with MPN. Furthermore, platelet P2Y₁₂ function, assayed by VASP, is inversely correlated with platelet and WBC counts in patients with MPN. Platelet P2Y₁₂ function also appears to be inversely correlated with JAK2V617F allele burden. This compromised P2Y₁₂ function may be a novel mechanism for the bleeding tendency associated with extreme thrombocytosis in MPN.

show abstract

“…(10,11). Bazal lökosit sayısı ve mutant JAK2 allel yükü göz önüne alınarak hastalık risk analizinin yapılacağı prospektif çalışmalara ihtiyaç vardır.…”

Section: İnterferon Alfaunclassified

Poli̇si̇temi̇a Vera: Patogenez, Teşhi̇s Ve Tedavi̇de Güncel Bi̇lgi̇ler

Yonal¹,

Sargin²

2015

İst Tıp Fak D

View full text Add to dashboard Cite

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by increased red blood cell mass and usually overproduction of granulocytes and platelets and increased spleen size. JAK2V617F mutation is present in more than 95% of PV patients. Bone marrow examination reveals excessive proliferation of erythroid, myeloid, and megakaryocytic elements. The prognosis of PV depends on the severity of the complications occurring during the clinical course. Thrombotic complications are the main cause of morbidity and mortality in PV. Survival is affected whether appropriate therapy is applied during the erythrocytotic phase of the disease. Uncontrolled erythrocytosis poses very high risk for development of thrombosis. Some studies suggest that PV patients have a normal or near-normal lifeexpectancy. Most studies, however, report excess mortality caused by thrombotic complications and acute leukemia transformation during course of PV. This review aims to highlight the pathogenesis, diagnosis and current management in PV.

show abstract

Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms

Cited by 29 publications

References 22 publications

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

Clinical and Laboratory Significance of Defective P2Y<sub>12</sub> Pathway Function in Patients with Myeloproliferative Neoplasms: A Pilot Study

Poli̇si̇temi̇a Vera: Patogenez, Teşhi̇s Ve Tedavi̇de Güncel Bi̇lgi̇ler

Contact Info

Product

Resources

About